Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| BioLineRx Ltd. | Motixafortide (BL-8040) and KEYTRUDA (pembrolizumab) | Pancreatic cancer | Phase 2a | Trial Discontinued | Motixafortide subcutaneous KEYTRUDA intravenous | Oncology |
| BioLineRx Ltd. | Motixafortide (BL-8040) - BLAST | Consolidation treatment for AML cancer patients | Phase 2b | Trial Discontinued | Subcutaneous | Oncology |
| BioMarin Pharmaceutical Inc. | PALYNZIQ (pegvaliase-pqpz) - (PEGASUS) | Phenylketonuria (PKU) in adolescents aged 12-17 | PDUFA priority review | Ongoing | Subcutaneous | Genetic Disorder |
| BioMarin Pharmaceutical Inc. | VOXZOGO | Hypochondroplasia | Phase 3 | Ongoing | Subcutaneous | Genetic Disorder |
| BioMarin Pharmaceutical Inc. | BMN 401 (INZ-701) - (ENERGY-2) | ENPP1 Deficiency | Phase 3 | Trial Planned | Subcutaneous | Genetic Disorder |
| BioMarin Pharmaceutical Inc. | Valoctocogene roxaparvovec (BMN 270-303) - (GENEr8-3) | Hemophilia A | Phase 3 | Ongoing | Intravenous | Hematology |
| BioMarin Pharmaceutical Inc. | BMN 401 (INZ-701) | ABCC6 deficiency | Phase 3 | Trial Planned | Subcutaneous | Genetic Disorder |
| Biomea Fusion Inc. | Icovamenib (BMF-219) with a GLP-1-Based Therapy - (COVALENT-211) | Diabetes and obesity | Phase 2b | Trial Planned | Oral | Endocrinology |
